Himura M: Anti-tumor necrosis factor therapy in patients with difficultto-treat lupus
Himura M: Anti-tumor necrosis factor therapy in patients with difficultto-treat lupus nephritis: a prospective series of nine patients. Clin Exp Rheumatol 2009, 27:416-421. Aringer M, Terodiline hydrochloride Houssiau F, Gordon C, Graninger WB, Voll RE, Rath E, Steiner G, Smolen JS: Adverse events and efficacy of TNF- blockade with infliximab in patients with systemic lupus erythematosus: long-term follow-up of 13 patients. Rheumatology (Oxford) 2009, 48:1451-1454. Baccala R, Hoebe K, Kono DH, Beutler B, Theofilopoulos AN: TLR-dependent and TLR-independent pathways of type I interferon induction in systemic autoimmunity. Nat Med 2007, 13:543-551. Santiago-Raber M-L, Baccala R, Haraldsson KM, Choubey D, Stewart TA, Kono DH, Theofilopoulos AN: Type-I interferon receptor deficiency reduces lupus-like disease in NZB mice. J Exp Med 2003, 197:777-788. Agrawal H, Jacob N, Carreras E, Bajana S, Putterman C, Turner S, Neas B, Mathian A, Koss MN, Stohl W, Kovats S, Jacob CO: Deficiency of type I IFN receptor in lupus-prone New PubMed ID:https://www.ncbi.nlm.nih.gov/pubmed/26572612 Zealand mixed 2328 mice decreases dendritic cell numbers and activation and protects from disease. J Immunol 2009, 183:6021-6029. Mathian A, Weinberg A, Gallegos M, Banchereau J, Koutouzov S: IFN- induces early lethal lupus in preautoimmune (New Zealand Black x New Zealand White) F1 but not in BALB/c mice. J Immunol 2005, 174:2499-2506. Fairhurst AM, Mathian A, Connolly JE, Wang A, Gray HF, George TA, Boudreaux CD, Zhou XJ, Li QZ, Koutouzov S, Banchereau J, Wakeland EK: Systemic IFN- drives kidney nephritis in B6.Sle123 mice. Eur J Immunol 2008, 38:1948-1960. Ramanujam M, Kahn P, Huang W, Tao H, Madaio MP, Factor SM, Davidson A: Interferon-alpha treatment of female (NZW x BXSB)F(1) mice mimics some but not all features associated with the Yaa mutation. Arthritis Rheum 2009, 60:1096-1101. Mathian A, Gallegos M, Pascual V, Banchereau J, Koutouzov S: Interferon- induces unabated production of short-lived plasma cells in preautoimmune lupus-prone (NZB X NZW)F1 mice but not in BALB/c mice. Eur J Immunol 2011, 41:863-872. Hron JD, Peng SL: Type I IFN protects against murine lupus. J Immunol 2004, 173:2134-2142. Li J, Liu Y, Xie C, Zhu J, Kreska D, Morel L, Mohan C: Deficiency of type I interferon contributes to Sle2-associated component lupus phenotypes. Arthritis Rheum 2005, 52:3063-3072. Nickerson KM, Christensen SR, Shupe J, Kashgarian M, Kim D, Elkon K, Shlomchik MJ: TLR9 regulates TLR7- and MyD88-dependent autoantibody production and disease in a murine model of lupus. J Immunol 2010, 184:1840-1848. Barrat FJ, Meeker T, Chan JH, Guiducci C, Coffmann RL: Treatment of lupusprone mice with a dual inhibitor of TLR7 and TLR9 leads to reduction of autoantibody production and amelioration of disease symptoms. Eur J Immunol 2007, 37:3582?586. Theofilopoulos AN, Baccala R, Beutler B, Kono DH: Type I interferons (alpha/ beta) in immunity and autoimmunity. Annu Rev Immunol 2005, 23:307-336. Niewold TB, Hua J, Lehman TJ, Harley JB, Crow MK: High serum IFN- activity is a heritable risk factor for systemic lupus erythematosus. Genes Immun 2007, 8:492-502. Niewold TB, Adler JE, Glenn SB, Lehman TJ, Harley JB, Crow MK: Age- andJacob and Stohl Arthritis Research Therapy 2011, 13:228 http://arthritis-research.com/content/13/4/Page PubMed ID:https://www.ncbi.nlm.nih.gov/pubmed/28493138 10 of18.104.22.168.22.214.171.124.126.96.36.199.188.8.131.52.184.108.40.206.sex-related patterns of serum interferon-alpha activity in lupus families. Arthritis Rheum 2008, 58:2113-2119. Kirou KA, Lee C, George S, Louca K, Peterson MG, Crow MK: Act.
Sorry, there was no activity found. Please try a different filter.